



CPC of America, Inc.

6336 17th Street Circle East
Sarasota Florida 34243
(941) 727-4370
FAX (941) 727-4371
www.cpa2000.com
Symbol: CPCF

July 10, 2008

To our Stockholders and Friends:

Through cooperation with the FDA and assistance from consultants, professionals and advisors, the Company is pleased to announce that it has achieved completion and approval of 90% of the subject criteria for restarting clinical trials in the U.S. that includes all items pertaining to the April 2007 FDA warning letter. The Company shall continue to interface with the FDA to satisfy the remaining 10% in order to receive full approvals and continue our clinical trials within the US in multiple clinical trial sites. During this process we are transitioning from a development stage to an operating company with the anticipated future commercialization of this technology and other applications of this intellectual property.

During this transition period the Company implemented the recommendations of the FDA in making some changes to its growing team of professionals, consultants and advisors to facilitate communications about the application of the MedClose™ VCS technology. Prior to the start of clinical investigations, this technology had been described as a “vascular closure device - VCD.” However, upon early clinical investigation results, the MedClose™ VCS is a crossover between a vascular closure device (an invasive closing procedure) which closes the opening from the inside of femoral artery and a wound device (a non invasive closing procedure) which closes openings from the outer surface of the artery wall. The MedClose™ VCS is an extra vascular closure system which closes outside of the vascular artery utilizing a biological sealant that creates an elastic coagulum that is easily absorbed by the body - typically within 10 - 14 days. In regulatory terms, this typical crossover technology is not an implant and neither supports or sustains life nor does it diagnose, cure, mitigate, treat or prevent disease; and as a result does not present the potential for serious risk to the health, safety, or welfare of a subject. However, the Company enthusiastically proceeds in the regulatory process as a significant risk determination without a regulatory explanation as of this date in the US. In the end the determination will be favorable upon the findings and analysis of the clinical trials. A recent study released in March 2008 led by study leader, Dr. Michael Kutcher, (Wake Forest University in Winston-Salem, N.C.) supports that even the application of Angioplasty is safe without a back-up open heart surgeon or open heart operating facilities. Thus the Company will continue to demonstrate, educate, inform and debate, as such, the features of the MedClose™ VCS medical device as to its design, use, primary mode of action, the safety and effectiveness that follow its use.

A transition from development to operating with the future commercialization of this intellectual property consists of three patents with two pending and some future anticipated submissions (as reported in 2003, 2004, & 2005 in future R&D applications). The market is beginning to move the closure segment into two product areas: (1) 6-9fr (2.0mm-3.0mm) for cardiac diagnostic, cardiac interventional, interventional radiology, interventional neuro radiology, carotid stenting and others, (2) 15-18fr (5.0mm-9.0mm) applications of closing the puncture site of the femoral artery. Our intellectual property reported has extensive capabilities and applications. However, our focus has been on the closing of the femoral artery as a Vascular Closure System. New developments and market segments look promising with ongoing studies being performed in countries around the world (by various suppliers) on additional cardiac treatments. The clinical aortic valve and mitral valve trials in Germany utilize the femoral artery as interventional treatment and corrective replacement procedures. The outcome of these trials (and others) is that the femoral artery opening is larger. In anticipation of this need the Company already has a solution to begin the final development, testing, etc. for a 15-18fr product line for future market growth and solutions utilizing the MedClose technology.

Through the Series E Private Placement Memorandum additional capital requirements in the amount of \$2,326,020.00 have been obtained. The Company will continue to work diligently to raise the balance of funds to achieve both our goals and to ensure the success of this development and commercialization of this exciting crossover technology of the MedClose™ VCS. While the overall domestic and world markets have been tumultuous for everyone in the first half of 2008, we thank you for your continued support.

Very truly yours,

/s/ Rod A. Shipman
Rod A. Shipman, Chief Executive Officer